Production (Stage)
Purple Biotech Ltd
PPBT
$2.61
-$0.09-3.33%
NASDAQ
| 12/31/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | 62.00K | -- | -- | 196.00K | |
| Gross Profit | -62.00K | -- | -- | -196.00K | |
| SG&A Expenses | 496.00K | 865.00K | 1.04M | 829.00K | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 1.02M | 3.26M | 4.47M | 6.27M | |
| Operating Income | -1.02M | -3.26M | -4.47M | -6.27M | |
| Income Before Tax | -415.00K | -2.42M | -3.78M | -4.86M | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -415.00K | -2.42M | -3.78M | -4.86M | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | 5.00K | 10.00K | 19.00K | 31.00K | |
| Net Income | -410.00K | -2.41M | -3.76M | -4.83M | |
| EBIT | -1.02M | -3.26M | -4.47M | -6.27M | |
| EBITDA | -1.01M | -3.21M | -4.42M | -6.26M | |
| EPS Basic | 0.00 | -0.01 | -2.78 | -0.02 | |
| Normalized Basic EPS | 0.00 | -0.01 | -- | -0.01 | |
| EPS Diluted | 0.00 | -0.01 | -2.78 | -0.02 | |
| Normalized Diluted EPS | 0.00 | -0.01 | -- | -0.01 | |
| Average Basic Shares Outstanding | 410.26M | 275.32M | 1.36M | 257.90M | |
| Average Diluted Shares Outstanding | 410.26M | 275.32M | 1.36M | 257.90M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |